Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.